April 2024 M T W T F S S 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 -
Join 20 other subscribers
Categories
- ADME
- Bioactivation
- Biotransformation
- Blood Brain Barrier
- Carcinogens
- Central Nervous System (CNS)
- Chemistry
- Company
- Conjugation Reactions
- Covalent Binding
- Cytochrome P450
- Definitions
- Disease
- DNA Adducts
- Drug Design
- Drug Drug Interaction (DDI)
- Drug Metabolism
- Drug Safety
- Drug Target
- Drugs
- Heterocycles
- Human Liver Microsomes(HLM)
- Idiosyncratic Effect
- Immune Response
- In Vitro/In Vivo Correlation
- Introduction
- Mass Spectrometry
- Mechanism-Based Inhibition (MBI)
- Med Chem
- Metabolic Stability
- Metabolite Identification (MetID)
- Metabolite Prediction
- Metabolite Profiling
- Metabolomics
- Mutagens
- Natrual Products
- Non-P450 enzymes
- P450 Phenotyping
- Pharmacokinetics (PK)
- Phase 2 Metabolism
- Physicochemical Properties
- Protein Adducts
- Radioisotope Label
- Reactive Intermediates
- SAR
- Solvent Effects
- Time-dependent Inhibition (TDI)
- Toxicity
- Uncategorized
Recently Viewed Posts
- Metabolically Stable tert-Butyl Replacement ACS Med Chem Lett 2013
- Deuterated Clopidogrel Analogues as a New Generation of Antiplatelet Agents ACS Med Chem Lett 2013
- Thiolactone Sulfoxides as New Reactive Metabolites Acting as Bis-Electrophiles: Implication in Clopidogrel and Prasugrel Bioactivation CRT 2013
- Which Metabolites Circulate? Minireview DMD 2013
- Boronic Acid-Containing Proteasome Inhibitors: Alert to Potential Pharmaceutical Bioactivation CRT 2013
Blogs I Follow
Category Archives: Pharmacokinetics (PK)
Pharmaceutical Profiling Case Study in Disruption ACS MCL 2013
Kerns, E. H. ACS Med. Chem. Lett., 2013, 4 (2), pp 150–152
ADMETchemist 